BOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco.
A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.
About Verve Therapeutics
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as pharmacologic targets for lowering low-density lipoprotein cholesterol (“LDL-C”), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Ashlea Kosikowski
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.13 |
| Daily Volume: | 0 |
| Market Cap: | US$994.020M |
May 14, 2025 April 11, 2025 February 27, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
